Articles de revues sur le sujet « Pricing – France »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Pricing – France ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.
Silberztein, Caroline. "France: New Transfer Pricing Rules." Intertax 24, Issue 6/7 (1996): 246–48. http://dx.doi.org/10.54648/taxi1996046.
Texte intégralLe Pen, Claude. "Drug Pricing and Reimbursement in France." PharmacoEconomics 10, Supplement 2 (1996): 26–36. http://dx.doi.org/10.2165/00019053-199600102-00006.
Texte intégralZielke, Rainer. "Transfer Pricing of Mayor EC Member Countries with Reference to the 2014 Corporate Income Tax Burden of the Thirty-Four OECD Member Countries Germany, France, United Kingdom, and Italy Compared." EC Tax Review 23, Issue 6 (2014): 332–51. http://dx.doi.org/10.54648/ecta2014032.
Texte intégralCarricano, Manu. "Pricing myopia: do leading companies capture the full value of their pricing strategies?" Management Decision 52, no. 1 (2014): 159–78. http://dx.doi.org/10.1108/md-03-2013-0184.
Texte intégralHellier, Emmanuelle. "Locally uniform water utility pricing. Social and economic issues in an emergent policy in France and Italy." Geopolitical, Social Security and Freedom Journal 1, no. 1 (2018): 152–70. http://dx.doi.org/10.2478/gssfj-2018-0008.
Texte intégralFriedeberg-Steward, Beatrix. "Pricing and Reimbursement of Pharmaceutical Products in France." Drug Information Journal 34, no. 4 (2000): 1201–5. http://dx.doi.org/10.1177/009286150003400427.
Texte intégralPandey, Asheesh, Sanjay Sehgal, Amiya Kumar Mohapatra, and Pradeepta Kumar Samanta. "Equity market anomalies in major European economies." Investment Management and Financial Innovations 18, no. 2 (2021): 245–60. http://dx.doi.org/10.21511/imfi.18(2).2021.20.
Texte intégralKilani, Moez, Ngagne Diop, and Daniel De Wolf. "A Multimodal Transport Model to Evaluate Transport Policies in the North of France." Sustainability 14, no. 3 (2022): 1535. http://dx.doi.org/10.3390/su14031535.
Texte intégralIllescas, Manzano María Dolores, Pérez Manuel Sánchez, and Puertas Sergio Martínez. "Why pricing hotel can have differences according to the country in which it is found?" Estudios de Economía Aplicada 37, no. 1 (2019): 122–37. https://doi.org/10.5281/zenodo.10622416.
Texte intégralCroguennec-Le Saout, Hélène. "Financial Reform of Public Policy on Ageing in France and the Persistent Invisibilization of Caregivers." Femina Politica – Zeitschrift für feministische Politikwissenschaft 33, no. 2-2024 (2024): 59–75. http://dx.doi.org/10.3224/feminapolitica.v33i2.05.
Texte intégralPelc, Alain, and Jean-Philippe Castan. "New Developments in Pricing and Drug Reimbursement in France." PharmacoEconomics 6, Supplement 1 (1994): 28–35. http://dx.doi.org/10.2165/00019053-199400061-00009.
Texte intégralGarcia, Serge, and Arnaud Reynaud. "Estimating the benefits of efficient water pricing in France." Resource and Energy Economics 26, no. 1 (2004): 1–25. http://dx.doi.org/10.1016/j.reseneeco.2003.05.001.
Texte intégralRodrigues, J., D. Bartels, L. Gundtoft, M. P. Planel, J. P. Sales, and T. A. Behnk. "PNS116 COMPARATIVE PRICING POLICY ANALYSIS BETWEEN DENMARK AND FRANCE." Value in Health 22 (November 2019): S781. http://dx.doi.org/10.1016/j.jval.2019.09.2018.
Texte intégralGRAND, H., A. L. Samson, and M. Aulois-Griot. "Orphan Drug Pricing In France: Influence of Main Factors." Value in Health 17, no. 7 (2014): A534. http://dx.doi.org/10.1016/j.jval.2014.08.1702.
Texte intégralMegerlin, Francis, and François Lhoste. "Innovation et réglementation du pricing des dispositifs médicaux en France." Santé Décision Management 12, no. 1-4 (2009): 69–84. http://dx.doi.org/10.3166/sdm.12.69-84.
Texte intégralBen Ali, Chiraz, and Cédric Lesage. "Audit pricing and nature of controlling shareholders: Evidence from France." China Journal of Accounting Research 6, no. 1 (2013): 21–34. http://dx.doi.org/10.1016/j.cjar.2012.08.002.
Texte intégralNatz, Alexander, and Marie-Geneviève Campion. "Pricing and reimbursement of innovative pharmaceuticals in France and the new healthcare reform." Farmeconomia. Health economics and therapeutic pathways 13, no. 2 (2012): 49–60. http://dx.doi.org/10.7175/fe.v13i2.270.
Texte intégralSánchez, Pérez Manuel, Manzano María Dolores Illescas, and Puertas Sergio Martínez. "Modeling hotel room pricing: A multi-country analysis." International Journal of Hospitality Management 79 (January 23, 2025): 89–99. https://doi.org/10.5281/zenodo.14728067.
Texte intégralVillemur, L., J. Cortes, and P. Gaugy. "HTA289 Analysis of the Reimbursement and Pricing of Vaccines in France." Value in Health 27, no. 12 (2024): S411. https://doi.org/10.1016/j.jval.2024.10.2114.
Texte intégralColla, Enrico, and Paul Lapoule. "Banning below‐cost resale in France: the impact on pricing decisions." International Journal of Retail & Distribution Management 36, no. 10 (2008): 746–58. http://dx.doi.org/10.1108/09590550810900973.
Texte intégralKaramti, Chiraz, and Lukasz Grzybowski. "Hedonic study on mobile telephony market in France: pricing–quality strategies." NETNOMICS: Economic Research and Electronic Networking 11, no. 3 (2010): 255–89. http://dx.doi.org/10.1007/s11066-010-9049-y.
Texte intégralMontginoul, Marielle. "Analysing the Diversity of Water Pricing Structures: The Case of France." Water Resources Management 21, no. 5 (2006): 861–71. http://dx.doi.org/10.1007/s11269-006-9104-5.
Texte intégralJai Pal Sharma, Pooja. "Mapping the Intellectual Structure of Asset Pricing: A Bibliometric Study." Review of Finance and Banking 16, no. 1 (2024): 57–71. http://dx.doi.org/10.24818/rfb.23.16.01.05.
Texte intégralRAIMOND, VÉRONIQUE C., WILLIAM B. FELDMAN, BENJAMIN N. ROME, and AARON S. KESSELHEIM. "Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation." Milbank Quarterly 99, no. 1 (2021): 240–72. http://dx.doi.org/10.1111/1468-0009.12507.
Texte intégralDubois, Pierre, and Laura Lasio. "Identifying Industry Margins with Price Constraints: Structural Estimation on Pharmaceuticals." American Economic Review 108, no. 12 (2018): 3685–724. http://dx.doi.org/10.1257/aer.20140202.
Texte intégralGilard, Martine, Frédérique Debroucker, Claude Dubray, et al. "Scientific Evaluation and Pricing of Medical Devices and Associated Procedures in France." Therapies 68, no. 4 (2013): 201–8. http://dx.doi.org/10.2515/therapie/2013036.
Texte intégralNiklitschek, T., A. E. Williams, and M. Storer. "PMS69 Key Drivers for Pricing and Reimbursement for Biologic Drugs in France." Value in Health 15, no. 7 (2012): A452. http://dx.doi.org/10.1016/j.jval.2012.08.1424.
Texte intégralTazi, N., and Y. Bouzidi. "Evolution of wind energy pricing policies in France: Opportunities and new challenges." Energy Reports 6 (February 2020): 687–92. http://dx.doi.org/10.1016/j.egyr.2019.09.050.
Texte intégralGaugy, P., and J. Cottin. "HTA136 Analysis of the Reimbursement and Pricing of Hybrid Medicines in France." Value in Health 26, no. 12 (2023): S345. http://dx.doi.org/10.1016/j.jval.2023.09.1820.
Texte intégralHerrenschmidt, Fleur. "The French Competition Council and Parallel Trade in the Pharmaceutical Industry: A Step Ahead of EU Case Law?" World Competition 31, Issue 2 (2008): 235–57. http://dx.doi.org/10.54648/woco2008019.
Texte intégralKockaya, Guvenc, Kagan Atikeler, Esin Tuna, et al. "Results of reference pricing and reimbursement discount rate schemes of Turkey." Farmeconomia. Health economics and therapeutic pathways 14, no. 2 (2013): 99–103. http://dx.doi.org/10.7175/fe.v14i2.473.
Texte intégralPavelková, Eva Mazegue, and Iva Živělová. "Pricing Electric Power in the Czech Republic and in Selected Countries." Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis 64, no. 3 (2016): 1001–11. http://dx.doi.org/10.11118/actaun201664031001.
Texte intégralMyungsu Hong. "A Study on the Predatory Pricing in EU Competition Law - France Telecom Case -." KYUNGPOOK NATIONAL UNIVERSITY LAW JOURNAL ll, no. 59 (2017): 259–84. http://dx.doi.org/10.17248/knulaw..59.201708.259.
Texte intégralCarval, G., M. Planel, and T. Zaccherini. "PMD160 - PRICING OF REIMBURSED MEDICAL DEVICES IN FRANCE: WHAT FACTORS IMPACT DECISION-MAKING?" Value in Health 21 (October 2018): S270. http://dx.doi.org/10.1016/j.jval.2018.09.1609.
Texte intégralMoutie, A. S., J. P. Sales, M. P. Planel, and J. Rodrigues. "PDG57 DRUG PRICING PREDICTABILITY IN FRANCE: WHICH MANAGED ENTRY AGREEMENT SUITS THE BEST?" Value in Health 22 (November 2019): S606. http://dx.doi.org/10.1016/j.jval.2019.09.1071.
Texte intégralRakhmayil, Sergiy. "Dating Capital Market Integration In The EMU." International Business & Economics Research Journal (IBER) 10, no. 3 (2011): 63. http://dx.doi.org/10.19030/iber.v10i3.4102.
Texte intégralMontginoul, M., J.-D. Rinaudo, Y. Lunet de Lajonquière, P. Garin, and J.-P. Marchal. "Simulating the impact of water pricing on households behaviour: the temptation of using untreated water." Water Policy 7, no. 5 (2005): 523–41. http://dx.doi.org/10.2166/wp.2005.0031.
Texte intégralRodwin, Marc A. "Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States." International Journal of Health Services 51, no. 3 (2021): 379–91. http://dx.doi.org/10.1177/0020731421996168.
Texte intégralSukmadilaga, Citra, Jose Christian Santoso, and Erlane K. Ghani. "Can Accounting Value Relevance and Pricing Error Influence Stock Price of High-Technology Service Enterprises?" Economies 11, no. 2 (2023): 48. http://dx.doi.org/10.3390/economies11020048.
Texte intégralBoutouria, Nahla, Salah Ben Hamad, and Imed Medhioub. "Option Valuation in the Presence of Market Sentiment: Application to Listed Companies in the CAC40 Index." Cognizance Journal of Multidisciplinary Studies 1, no. 9 (2021): 1–11. http://dx.doi.org/10.47760/cognizance.2021.v01i09.001.
Texte intégralNahla, Boutouria, Ben Hamad Salah, and Medhioub Imed. "Option Valuation in the Presence of Market Sentiment: Application to Listed Companies in the CAC40 Index." Cognizance Journal of Multidisciplinary Studies 1, no. 9 (2021): 1–11. https://doi.org/10.47760/cognizance.2021.v01i09.001.
Texte intégralGregg, Emily, Karina Watts, Charlotte Graham, and Stuart Mealing. "PD195 Variation In Decision-Making And Market Access Routes For Vaccines: Insights From Seven Countries." International Journal of Technology Assessment in Health Care 40, S1 (2024): S167. https://doi.org/10.1017/s0266462324004173.
Texte intégralLeurent, Fabien, and Sheng Li. "Between Pricing and Investment, What Mobility Policies Would Be Advantageous for Île-de-France?" Journal of Advanced Transportation 2020 (December 19, 2020): 1–13. http://dx.doi.org/10.1155/2020/8859913.
Texte intégralPandey, Asheesh, and Rajni Joshi. "Examining Asset Pricing Anomalies: Evidence from Europe." Business Perspectives and Research, July 30, 2021, 227853372110257. http://dx.doi.org/10.1177/22785337211025712.
Texte intégralDouvier, P. J., and X. Daluzeau. "New Transfer Pricing Documentation Obligations for Large Companies." International Transfer Pricing Journal 21, no. 3 (2014). http://dx.doi.org/10.59403/3f0zjn2.
Texte intégral"Reference pricing to be introduced in France." PharmacoEconomics & Outcomes News 207, no. 1 (1999): 11. http://dx.doi.org/10.1007/bf03274919.
Texte intégralPelen, F. "Reimbursement and Pricing of Drugs in France." HEPAC Health Economics in Prevention and Care, March 1, 2000, 20–23. http://dx.doi.org/10.1007/s101980070019.
Texte intégral"No agreement on Bronchitol pricing in France." PharmacoEconomics & Outcomes News 686, no. 1 (2013): 11. http://dx.doi.org/10.1007/s40274-013-0701-2.
Texte intégral"France cuts novel pricing deal for celecoxib." PharmacoEconomics & Outcomes News 299, no. 1 (2001): 12. http://dx.doi.org/10.1007/bf03269170.
Texte intégralLe Bris, David, Olivier Gergaud, Debrah C. Meloso, and Ronan Tallec. "Buyback option pricing in Old Regime France." SSRN Electronic Journal, 2024. http://dx.doi.org/10.2139/ssrn.4824006.
Texte intégral